- Biogen Inc. (BIIB)
- Intuitive Surgical Inc. (ISRG)
- AbbVie Inc. (ABBV)
- Eli Lilly and Company (LLY)
- Repligen Corporation (RGEN)
Q: Repligen is trading close to the 52-week low and would welcome your analysis of their recent operating performance and market potential looking forward. Post-pandemic and mindful of competitors in the same space does their stock have any opportunity to excel in the coming year, and if held as a position in a long-term growth portfolio, could you please rank the appeal of Repligen in descending order versus your go-to favorites in the same general space. Thanks kindly for your thoughts.